Purpose: To investigate the clinical outcomes of patients with primary and metastatic lung tumors treated by CyberKnife(superscript ®) (CK) stereotactic body radiotherapy (SBRT).Methods: Between November 2005 and June 2008, we treated 19 patients with SBRT at Taipei Medical University-Wan Fang Hospital. The SBRT was delivered by CK tumor tracking system. Tumor response and treatment-related toxicity were evaluated by follow-up image study. Treatment-related toxicities were scored by Common Terminology Criteria for Adverse Events version 3.0. In this study, we reviewed their medical records retrospectively.Results: We treated 47 lung tumors in 19 patients using CK SBRT. Eleven tumors in 8 patients were primary lung cancer, and 36 tumors in 11 patients were metastatic lung cancer. The locations of 9 tumors were central, whereas the others were peripheral. The tumor volumes were ranged from 1.1 to 110.5 ml (median, 9.5 ml). The radiation doses were ranged from 22 to 60 Gy, given in 2 to 4 fractions. The prescribed doses were normalized at 76% to 85% of the planned isodose. With a median follow-up interval of 12 months, we observed that grade 2 radiation pneumonitis (RP) occurred in 3 patients (1 central; 2 peripheral), whereas we found that grade 3 RP occurred in 2 patients with central lesions. According to the univariate analysis, female (p=0.038) and central lesion (p=0.042) were two predictive factors to the occurrence of grade≥2 RP. One grade 4 tracheal complication (tracheoesophageal fistula) and one grade 5 bronchial complication (bronchial necrosis) were observed in two patients who had centrally located recurrent tumors and had been previous treated with external beam radiotherapy. Four of the evaluable patients (16 patients) had responded completely (25%), seven exhibited partial response to treatment (43.8%), and two had stable disease (12.5%). Three patients had tumor progression after SBRT (18.7%). The 1-year overall survival (OS) was 63%, and the 1-year local progression-free survival (PFS) was 84.2%. The 1-year local PFS was 87.5% for primary lung cancer and 81.8% for metastatic lung cancer (p=0.87). The 1-year local PFS for central and peripheral lesions was 80% and 85.7%, respectively (p=0.63).Conclusion: Our study showed that SBRT using the CK system was effective for treating primary and metastatic lung tumors, providing better local control and shorter treatment course compared with those treated with conventional fractionated radiotherapy. Our study also showed two predicting factors for RP. Finally, using SBRT to treat centrally located tumor or re-irradiate recurrent tumor require additional caution due to higher risk of having complication. Thus, we suggest that more studies are needed in the future to confirm those findings in this study.
Translated title of the contribution使用立體定位體部放射治療於原發性和轉移性肺腫瘤病患之早期經驗
Original languageEnglish
Pages (from-to)111-124
Number of pages14
Issue number2
Publication statusPublished - 2011


  • 電腦刀
  • 立體定位體部放射治療
  • 肺腫瘤
  • 放射性肺炎
  • CyberKnife(superscript ®)
  • Stereotactic body radiotherapy
  • Lung tumor
  • Radiation pneumonitis


Dive into the research topics of 'Early Experience of Stereotactic Body Radiotherapy in Patients with Primary and Metastatic Lung Tumors'. Together they form a unique fingerprint.

Cite this